https://www.selleckchem.com/pr....oducts/dihydroethidi
ded value to the usual risk assessment of STEMI patients. GDF-15 and NT-proBNP added value to the usual risk assessment of STEMI patients.Mutations in SF3B1 are found in 20% of myelodysplastic syndromes and 5-10% of myeloproliferative neoplasms, where they are considered important for diagnosis and therapy decisions. Sanger sequencing and NGS are the currently available methods to identify SF3B1 mutations, but both are time-consuming and expensive techniques that are not practicable in most small-/medium-sized laboratories. To i
Curtir
Comentario
Compartilhar
